Therapeutic efficacy of aerosolized moxifloxacin in respiratory tract infection in goats

Abstract

A total of 24 goats age between 3 months to 4 years used in study were selected on the basis of clinical parameters. Deep nasal swabs collected for bacterial culture and sensitivity reviled more isolates of coagulase positive Staphylococcus spp. and maximum sensitivity to moxifloxacin. Goats were assigned to three groups of eight goats each. Group I was healthy control, group II treated with moxifloxacin @ 5 mg/kg body weight given intramuscularly and group III was treated with aerosolized moxifloxacin @ 5 mg/kg body weight given through nasal route. Hematological profile and oxidative stress indices were used for comparative efficacy of nebulizer therapy with standard therapy and parameters were compared to the healthy controls. There was improvement in the parameters (p<0.05) in group III than with group II. We concluded that aerosolized moxifloxacin @ 5 mg/kg body weight can be used as alternative therapeutic modality for respiratory tract infection in goats.